SPRT

American Riviera Bancorp Announces Changes to Board Leadership

Retrieved on: 
Friday, June 23, 2023

American Riviera Bancorp (“Company”) (OTCQX: ARBV), holding company of American Riviera Bank (“Bank”), announced today changes in its Board leadership associated with normal succession planning.

Key Points: 
  • American Riviera Bancorp (“Company”) (OTCQX: ARBV), holding company of American Riviera Bank (“Bank”), announced today changes in its Board leadership associated with normal succession planning.
  • After seventeen years of extraordinary leadership as Board Chairperson, Lawrence Koppelman, a founder of the Bank has assumed a board member-at-large position with the Company and Bank.
  • American Riviera Bank would not be where we are today without Larry’s statesmanship, wisdom, and dedication.”
    After seventeen years of serving as Board Vice Chairperson, Darren Caesar, a founder of the Bank was elected by his peers to serve as Board Chairperson of the Company and Bank.
  • American Riviera Bank, the 100% owned subsidiary of American Riviera Bancorp, is a full-service community bank focused on serving the lending and deposit needs of businesses and consumers on the Central Coast of California.

Hestia Capital Issues Statement From its Unaffiliated Director Candidates and Shares Key Facts to Reinforce the Urgent Need for Meaningful Change at Pitney Bowes

Retrieved on: 
Wednesday, April 19, 2023

We recognize that our respective slates simply have different visions for transforming Pitney Bowes.”

Key Points: 
  • We recognize that our respective slates simply have different visions for transforming Pitney Bowes.”
    Separately, Hestia is sharing the below facts that reinforce the urgent need for changes in leadership and strategy.
  • Fact: Pitney Bowes purchased Borderfree for $395 million in 2015 and sold it for $100 million in 2022, representing a 75% loss on stockholders’ investment.
  • Notably, each new director appointed during Mr. Lautenbach’s first 10 years of service had a connection to at least one other sitting director.
  • As a reminder, Hestia is seeking to elect five highly qualified and independent candidates to Pitney Bowes’ nine-member Board at the Company’s Annual Meeting on May 9, 2023.

Hestia Capital Issues Letter to Pitney Bowes Stockholders from Lance Rosenzweig, its Proposed Interim CEO and a Proven Turnaround Expert

Retrieved on: 
Tuesday, April 4, 2023

To maximize the likelihood of a turnaround at Pitney Bowes, we urge you to vote for Hestia’s full slate on the WHITE proxy card or WHITE voting instruction form.

Key Points: 
  • To maximize the likelihood of a turnaround at Pitney Bowes, we urge you to vote for Hestia’s full slate on the WHITE proxy card or WHITE voting instruction form.
  • These will be the pillars of the turnaround strategy (described in more detail below) which I intend to help a reconstituted Board implement.
  • I was introduced to Hestia last fall as someone who could provide insight on turning around Pitney Bowes.
  • The segment includes a legacy postage meter business, a newer and subscale shipping label software business, and the Pitney Bowes Bank.

Farmer Bros. Co. Announces Board Refresh and Cooperation Agreement with Stockholders JCP Investment Management and 22NW

Retrieved on: 
Monday, October 31, 2022

Under the Cooperation Agreement, the Company has agreed to promptly appoint Bradley L. Radoff as an independent member of the Board of Directors (the Board).

Key Points: 
  • Under the Cooperation Agreement, the Company has agreed to promptly appoint Bradley L. Radoff as an independent member of the Board of Directors (the Board).
  • Following the 2022 Annual Meeting, Christopher P. Mottern will retire from the Board, effective as of June 30, 2023.
  • During the term of the Cooperation Agreement, JCP and 22NW have also agreed to customary standstill provisions and voting commitments.
  • We also look forward to continuing to work with our stockholders, JCP and 22NW, going forward.

Tim Krozek Joins the Windfall Leadership Team as Chief Revenue Officer

Retrieved on: 
Wednesday, September 7, 2022

SAN FRANCISCO, Sept. 7, 2022 /PRNewswire-PRWeb/ -- Windfall Data, Inc. ("Windfall"), the most trusted and accurate provider of insights and democratized intelligence on people, announced today that Tim Krozek has been named Chief Revenue Officer ("CRO"). In this role, Krozek will oversee Windfall's go-to-market functions including Sales, Revenue Operations, Customer Success, and Marketing. He will focus Windfall's 100% year-over-year growth and tremendous customer momentum into a strategic execution plan across revenue-generating teams.

Key Points: 
  • In this role, Krozek will oversee Windfall's go-to-market functions including Sales, Revenue Operations, Customer Success, and Marketing.
  • "With the massive growth Windfall has experienced over the last year, we are thrilled to welcome Tim to the team," said Arup Banerjee, CEO and Co-Founder of Windfall.
  • "His extensive background in data and digital marketing, combined with our shared customer-first vision of how to continue to deliver while we grow, makes Tim the perfect addition to our leadership team.
  • Tim brings two decades of leadership and revenue generation success from building businesses in both enterprise and start-up environments.

Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors

Retrieved on: 
Monday, January 3, 2022

NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Companys Board of Directors (the Board), effective immediately.

Key Points: 
  • NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Companys Board of Directors (the Board), effective immediately.
  • The Company also announced that directors Dov Perlysky and Rebecca Fischer will step down from the Board immediately to facilitate a smooth transition for the new Board members.
  • On behalf of the entire Board, I also want to extend our appreciation to both Dov and Rebecca for their guidance and service to Enzo Biochem.
  • Messrs. Erfanian and Radoff will stand for election at Enzo Biochems upcoming annual meeting (the Annual Meeting).

JT Medical Announces the Company is Accepting New MOUs in Addition to Its Current Two

Retrieved on: 
Thursday, October 28, 2021

MAYFIELD, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- JT Medical (the Company), JT Medical announces that it is now accepting memorandums of understanding (MOUs) from researchers wishing to secure high quality, repeatable batch, plant-based medical products derived from regulated plants, including but not limited to, cannabis, psilocybin mushroom, and peyote.

Key Points: 
  • MAYFIELD, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- JT Medical (the Company), JT Medical announces that it is now accepting memorandums of understanding (MOUs) from researchers wishing to secure high quality, repeatable batch, plant-based medical products derived from regulated plants, including but not limited to, cannabis, psilocybin mushroom, and peyote.
  • As supply capacity is limited, subsequent MOUs will be prioritized on a first-come basis.
  • Additional capacity will be provided based on the number and size of MOUs that proceed to a definitive agreement.
  • Production, process, and distribution of plant-based products will be under license from the U.S. Food and Drug Administration (DEA) to be granted to JT Medical.

Bradley L. Radoff Issues Open Letter to Recently-Appointed Independent Directors of Enzo Biochem

Retrieved on: 
Tuesday, October 19, 2021

We need you to be change agents in the boardroom, not rubberstamped votes for Dr. Rabbani.

Key Points: 
  • We need you to be change agents in the boardroom, not rubberstamped votes for Dr. Rabbani.
  • The participants in the proxy solicitation are anticipated to be The Radoff Family Foundation, a Texas non-profit corporation (Radoff Foundation), Bradley L. Radoff and Lorrie A. Carr.
  • As of the date hereof, Radoff Foundations directly beneficially owns 400,000 shares of common stock, par value $0.01 per share, of the Company (Common Stock).
  • As of the date hereof, Mr. Radoff directly beneficially owns 3,075,100 shares of Common Stock.

Sprout AI’s Rapid Expansion Continues During Daunting Times

Retrieved on: 
Thursday, October 7, 2021

Sprout AI remains on track to increase its total number of full-time staff to over 80 individuals by end of Q2 2022.

Key Points: 
  • Sprout AI remains on track to increase its total number of full-time staff to over 80 individuals by end of Q2 2022.
  • Accordingly, to further assist with expansion into the Oceania Region and to provide marketing, sales and technical support to Africa and Asia, Sprout AI has incorporated a fully owned subsidiary in Australia (Sprout AI Australia Pty.
  • Chris Bolton, CEO of Sprout AI, commented: "The challenges presented to any business in 2020 and 2021 were daunting.
  • Being positioned within Panama Pacifico has ensured Sprout AI maintains a distinct competitive advantage over its nearest competitors and provides Sprout AI with a stable base to further realize our dream of global expansion.

Sprout AI Inc. Announces Initial Sales Order

Retrieved on: 
Tuesday, September 21, 2021

VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire Sprout AI Inc. (Sprout AI or the Company) (CSE: SPRT) is a technologically focused, sustainable vertical farming company that has developed scalable, controlled aeroponic cultivation habitats.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire Sprout AI Inc. (Sprout AI or the Company) (CSE: SPRT) is a technologically focused, sustainable vertical farming company that has developed scalable, controlled aeroponic cultivation habitats.
  • Under the terms of the Order, an initial payment of 50% is required at the time of the Order to commence assembly.
  • Sprout AI CEO Chris Bolton commented: Sprout AIs selection by JT Medical as their choice indoor vertical cultivation technology represents an additional key milestone for the Company.
  • Utilizing Sprout AI for this DEA medical research license Project further demonstrates Sprout AIs highest level of plant crop flexibility, quality and repeatability.